Cargando…

Gastrin-Releasing Peptide Receptor Antagonist [(68)Ga]RM2 PET/CT for Staging of Pre-Treated, Metastasized Breast Cancer

SIMPLE SUMMARY: [(68)Ga]RM2 positron emission tomography (PET)/computed tomography (CT) has shown to be a promising imaging method for primary breast cancer (BC) with positive estrogen receptor (ER) status, but it has not been tested for visualization of metastasized recurrent or progressive BC. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michalski, Kerstin, Kemna, Lars, Asberger, Jasmin, Grosu, Anca L., Meyer, Philipp T., Ruf, Juri, Sprave, Tanja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656859/ https://www.ncbi.nlm.nih.gov/pubmed/34885214 http://dx.doi.org/10.3390/cancers13236106

Ejemplares similares

[(68)Ga]Ga-RM2 PET/CT reveals small distant metastases not detected by conventional imaging in primary estrogen receptor-positive breast cancer
por: Michalski, Kerstin, et al.
Publicado: (2023)

Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET
por: Stoykow, Christian, et al.
Publicado: (2016)

(68)Ga-Radiolabeling and Pharmacological Characterization of a Kit-Based Formulation of the Gastrin-Releasing Peptide Receptor (GRP-R) Antagonist RM2 for Convenient Preparation of [(68)Ga]Ga-RM2
por: Chastel, Adrien, et al.
Publicado: (2021)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

The effects of novel macrocyclic chelates on the targeting properties of the (68)Ga-labeled Gastrin releasing peptide receptor antagonist RM2
por: Wang, Yinwen, et al.
Publicado: (2023)

Intraindividual comparison between (68)Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients
por: Spohn, Simon, et al.
Publicado: (2020)

Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist (68)Ga-RM2 and (18)F-FDG in breast cancer samples
por: Morgat, Clément, et al.
Publicado: (2019)

Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN(7–14) and Antagonist RM26
por: Cheng, Siyuan, et al.
Publicado: (2017)

First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist (68)Ga-NODAGA-MJ9
por: Gnesin, Silvano, et al.
Publicado: (2018)

[(68)Ga]Ga-PSMA and [(68)Ga]Ga-RM2 PET/MRI vs. Histopathological Images in Prostate Cancer: A New Workflow for Spatial Co-Registration
por: Ghezzo, Samuele, et al.
Publicado: (2023)

(68)Ga-PSMA and (68)Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data
por: Mapelli, Paola, et al.
Publicado: (2022)

Imaging Properties and Tumor Targeting of (68)Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
por: Gruber, Leonhard, et al.
Publicado: (2022)

Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men
por: Wieser, Gesche, et al.
Publicado: (2014)

Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of (68)Ga-PSMA and (68)Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients
por: Mapelli, Paola, et al.
Publicado: (2021)

(68)Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer
por: Damjanovic, Jonathan, et al.
Publicado: (2019)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

Uncovering the invisible—prevalence, characteristics, and radiomics feature–based detection of visually undetectable intraprostatic tumor lesions in (68)GaPSMA-11 PET images of patients with primary prostate cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2020)

Combining (68)Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study
por: Kirste, Simon, et al.
Publicado: (2021)

(68)Ga-PSMA-PET/CT for the evaluation of pulmonary metastases and opacities in patients with prostate cancer
por: Damjanovic, Jonathan, et al.
Publicado: (2018)

Widespread micronodular hepatic metastases of neuroendocrine tumor detected by [(68)Ga]DOTATATE PET/CT
por: D'Souza, Julia C., et al.
Publicado: (2022)

(68)Ga DOTATATE Uptake in Hemangioma Simulating Metastasis on PET Imaging: CT helps characterize bone hemangioma that could be wrongly interpreted as skeletal metastases on (68)Ga DOTATATE PET imaging
por: Vertenten, Bart, et al.
Publicado: (2019)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

Value of (68)Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [(18)F]fluoromethylcholine PET-CT and multiparametric MRI—a phase I/II study
por: Beheshti, Mohsen, et al.
Publicado: (2022)

Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT
por: Kunz, Wolfgang G., et al.
Publicado: (2018)

Impact of (68)Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors
por: Kosmala, Aleksander, et al.
Publicado: (2023)

Accuracy of PET quantification in [(68)Ga]Ga-pentixafor PET/MR imaging of carotid plaques
por: Rausch, Ivo, et al.
Publicado: (2020)

Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With De Novo Lymph Node-Positive Prostate Cancer
por: Spohn, Simon K.B., et al.
Publicado: (2022)

Localization of Pyelonephritis by (68)Ga-FAPI PET CT
por: Jagtap, Rajlaxmi Rangrao, et al.
Publicado: (2023)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

Diagnostic challenges in a patient with an occult insulinoma:(68 )Ga‐DOTA‐exendin‐4 PET/CT and (68)Ga‐DOTATATE PET/CT
por: Bongetti, Elisa, et al.
Publicado: (2018)

Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases
por: Savelli, Giordano, et al.
Publicado: (2014)

Atypical metastases from prostate cancer detected on 68Ga-PSMA PET/CT: a case series
por: Yamaga, Lilian Yuri Itaya, et al.
Publicado: (2020)

A Case of Pancreatic Neuroendocrine Tumor With Extensive Skeletal Metastases Detected on 68Ga-DOTANOC PET-CT
por: Wakankar, Ritwik
Publicado: (2023)

The Role of [(68)Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review
por: Albano, Domenico, et al.
Publicado: (2022)

Intra-individual qualitative and quantitative comparison of [(68)Ga]Ga-DOTATATE PET/CT and PET/MRI
por: Lens, Géraldine, et al.
Publicado: (2023)

Artificial intelligence-based (68)Ga-DOTATOC PET denoising for optimizing (68)Ge/(68)Ga generator use throughout its lifetime
por: Quak, Elske, et al.
Publicado: (2023)

(68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison
por: Zamboglou, Constantinos, et al.
Publicado: (2016)

Prospective data-driven respiratory gating of [(68)Ga]Ga-DOTATOC PET/CT
por: Sigfridsson, Jonathan, et al.
Publicado: (2021)

PET-CT imaging of pulmonary inflammation using [(68)Ga]Ga-DOTA-TATE
por: Puuvuori, Emmi, et al.
Publicado: (2022)

Evaluation of [(68)Ga]Ga-NODAGA-RGD for PET Imaging of Rat Autoimmune Myocarditis
por: Jahandideh, Arghavan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sj67qe1ik3uqrauicuad2g7uoc